Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Mycobacterial cyt-<i>bc</i><sub>1</sub><i>:aac<sub>3</sub></i> Oxidase as a Drug Target: Activities of Arylvinylpiperazine Amides and Aminoquinazolines against <i>Mycobacterium ulcerans</i>.

Journal of medicinal chemistry·2026

Same author

Engaging With Hospital Staff to Develop Implementation Strategies For Delivering a Patient Falls Prevention Education Program Using a World Café.

Western journal of nursing research·2026

Same author

An atlas of microtubule lattice parameters regulated through ligand binding to the microtubule-stabilizing sites.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

MechanoAge, a machine learning platform to identify individuals susceptible to breast cancer based on mechanical properties of single cells.

EBioMedicine·2026

Same author

Illuminating chromaffin granules: compartmentalization of endocannabinoids in bovine adrenal glands supports role in hormone modulation.

Biochemical pharmacology·2026

Same author

Studies toward the Total Synthesis of Griseoviridin.

Organic letters·2026

Search research articles

Related Experiment Video

Updated: May 6, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Contextual compound screening for improved therapeutic discovery.

Lasse Evensen¹, Kristin Odlo, David R Micklem

¹Department of Biomedicine, University of Bergen, Jonas Lies Vei 91, 5009 Bergen (Norway).

Chembiochem : a European Journal of Chemical Biology

|November 14, 2013

Summary

This study developed an in vitro model to test drug effectiveness by mimicking the tumor microenvironment. The model identified new compounds that disrupt tumor blood vessel formation in vivo.

Keywords:

angiogenesis cancer combretastatin compound screening vascular disruption

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

Related Experiment Videos

Last Updated: May 6, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

Area of Science:

* Cellular Biology
* Pharmacology
* Biomedical Engineering

Background:

* Cellular behavior and drug sensitivity are influenced by systemic and microenvironmental factors.
* In vitro models that replicate cellular behavior in context are crucial for therapeutic development.
* Angiogenesis, the formation of new blood vessels, is a complex process involving endothelial cells, growth factors, and the vascular extracellular matrix.

Purpose of the Study:

* To develop and utilize an in vitro organotypic contextual screening approach to model angiogenesis.
* To analyze the structure-activity relationships of combretastatin A-4 analogues.
* To identify novel compounds with potent in vivo vascular-disrupting activity.

Main Methods:

* Co-culture of primary human vascular cells to self-assemble into capillary-like structures, mimicking angiogenic context.
* Temporal live-cell imaging-based analysis to delineate unique angiogenic microenvironments.
* Quantification of contextual activity of compound inhibitors using the developed in vitro model.

Main Results:

* The in vitro organotypic contextual screening approach successfully modeled angiogenic dynamics.
* Structure-activity relationship analysis was performed on a combretastatin A-4 analogue series.
* Novel compounds with potent vascular-disrupting activity were identified.

Conclusions:

* In vitro models that mimic the angiogenic microenvironment are valuable for therapeutic development.
* The developed screening approach enables the identification of potent vascular-disrupting compounds.
* This research contributes to the discovery of novel anti-angiogenic agents for cancer therapy.